TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 356792
Drug: Triamcinolone acetonide
Normalized name: Triamcinolone Acetonide
DrugBank: Triamcinolone (DB00620)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Triamcinolone acetonide aerosol, 800 microgram daily
Study: 23241048
Drug: Pregabalin 300,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pregabalin 300, 450 and 600 mg/day
Study: 18184631
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg elemental zinc per day
Study: 17015057
Drug: Intravenous midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous midazolam (0.25 mg/kg)
Study: 17015057
Drug: Low midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low midazolam clearance (<9.5 mL x kg(‐1) x min(‐1))
Study: 11078841
Drug: Low-dose radiotherapy
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose radiotherapy (20 Gy of 6-MV photons to the macula of the affected eye)
Study: 3371094
Drug: Oxygen delivered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxygen delivered by nasal prongs (3 L/min)
Study: 3371094
Drug: Oxygen delivered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxygen delivered by economizer (3 L/min)
Study: 30021626
Drug: Cocoa-based products
Normalized name: cocoa butter Topical Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cocoa-based products (mean intake 618.7 mg/day)
Study: 30021626
Drug: Red wine
Normalized name: Red wine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Red wine (mean intake 123.7 mg/day)
Study: 26744107
Drug: Adjuvant interferon
Normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant interferon alfa‐2b (IFN) therapy
Study: 25515708
Drug: Long pulsed
Normalized name: long pepper extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Long pulsed 1064 nm Nd:YAG laser (LPND) treatment with three passes at a spot size of 12 mm, 20-24 J/cm² fluence, 12 ms width, and frequency of 2 Hz, for three sessions every four weeks
Study: 20307245
Drug: Surgery plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgery plus adjuvant 5-fluorouracil (5-FU)-based chemotherapy
Study: 18250501
Drug: Enteral rhEPO
Normalized name: lipase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enteral rhEPO 400 U/kg, three times/week, plus FeSO4 3-6 mg/Kg/day (Study group)
Study: 16368469
Drug: Hormone Therapy
Normalized name: INVESTIGATIONAL HORMONE THERAPY/REPLACEMENT,OTHER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hormone Therapy (HT) - 1mg estradiol + 0.5 mg norethisterone acetate
Study: 12797703
Drug: Aminophylline 7.35
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aminophylline 7.35 mg/kg/day intravenously combined with anti-tuberculosis agents (isoniazid, rifampicin, ethambutol, pyrazinamide)
Study: 11156459
Drug: Rectal compliance
Normalized name: ribavirin
DrugBank: Ribavirin (DB00811)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Rectal compliance measurement using a latex rectal balloon filled with water at a rate of 60 ml per minute.
Study: 7930085
Drug: Pre-admission programme
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pre-admission programme for psychological preparation (videotape, tour, hospital play)
Study: 3294976
Drug: Inhaled albuterol
Normalized name: albuterol Inhalation Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled albuterol (2 puffs)
Study: 3294976
Drug: Inhaled metaproterenol
Normalized name: metaproterenol Inhalation Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled metaproterenol (2 puffs)
Study: 3294976
Drug: Inhaled albuterol
Normalized name: albuterol Inhalation Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled albuterol (1 puff)
Study: 3294976
Drug: Inhaled metaproterenol
Normalized name: metaproterenol Inhalation Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled metaproterenol (1 puff)
Study: 29519283
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment group (lateral position ventilation + vibration sputum drainage)
Study: 27614450
Drug: Tangyiping Granules
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tangyiping Granules (TYP) 10 g twice daily for 12 weeks
Study: 25360512
Drug: Lemon balm
Normalized name: LEMON BALM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lemon balm preparation in a beverage
Study: 25360512
Drug: Lemon balm
Normalized name: LEMON BALM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lemon balm preparation in yoghurt
Study: 23220316
Drug: Group 4:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group 4: capsules pre-warmed and photocuring delayed for 2.4 minutes
Study: 18484971
Drug: Ezetimibe 40
Normalized name: EZETIMIBE 40MG/SIMVASTATIN 10MG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ezetimibe 40 mg/day
Study: 12859261
Drug: Timolol maleate/dorzolamide
Normalized name: timolol maleate/dorzolamide HCl/bimatoprost/PF 0.5 %-2 %-0.01 % OPHTHALMIC DROPS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Timolol maleate/dorzolamide fixed combination (TDFC)
Study: 12859261
Drug: Timolol maleate/pilocarpine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Timolol maleate/pilocarpine fixed combination (TPFC)
Study: 8971300
Drug: Lansoprazole 30
Normalized name: lansoprazole 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lansoprazole 30 mg once daily, amoxycillin 1000 mg b.d., clarithromycin 250 mg b.d. for 7 days (LAC group)
Study: 8971300
Drug: Lansoprazole 30
Normalized name: lansoprazole 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lansoprazole 30 mg once daily, amoxycillin 1000 mg b.d. for 7 days, plus azithromycin 500 mg once daily for 3 days (LAA group)
Study: 6441544
Drug: Nicardipine (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicardipine (mean dose: 69.4 mg per day, given three times a day)
Study: 31612844
Drug: 0.8 Ratio
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.8 Ratio of End-Expired Agent Concentration to Inspired Agent Concentration (group R)
Study: 27577516
Drug: Split-bolus spectral
Normalized name: Peumus boldus leaf extract
DrugBank: Boldo leaf extract (DB15815)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Split-bolus spectral MDCT with virtual unenhanced imaging (1.5 mL/kg body weight, 4 mL/s flow rate)
Study: 27577516
Drug: Conventional tri-phasic
Normalized name: Nu Skin Tri-Phasic White System KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional tri-phasic enhanced CT (1.5 mL/kg body weight, 4 mL/s flow rate)
Study: 2576200
Drug: Mepindolol (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mepindolol (20 mg/9.8 cm2 patch)
Study: 2576200
Drug: Propranolol (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol (40 mg/9.8 cm2 patch)
Study: 23483
Drug: oral allopurinol
Normalized name: Allopurinol
DrugBank: Allopurinol (DB00437)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: oral allopurinol
Study: 23483
Drug: sublingual procaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: sublingual procaine adenylate
Study: 28808905
Drug: 801-mg tablet
Normalized name: pirfenidone 801 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 801-mg tablet (fasted state)
Study: 28808905
Drug: 801-mg tablet
Normalized name: pirfenidone 801 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 801-mg tablet (fed state)
Study: 28808905
Drug: Capsules (fasted
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsules (fasted state)
Study: 28808905
Drug: Capsules (fed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsules (fed state)
Study: 16330517
Drug: Post-treatment follow-up
Normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Post-treatment follow-up and investigation
Study: 11252695
Drug: Antioxidant supplementation
Normalized name: antioxidant 119
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antioxidant supplementation (4 capsules/day, each containing 250 mg of L‐ascorbic acid, 100 IU of dl‐a‐tocopherol acetate, and 150 mg of alpha‐lipoic acid)
Study: 8272392
Drug: Simple out‐patient
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simple out‐patient treatment
Study: 30499426
Drug: Daily broccoli
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily broccoli consumption (200 g cooked broccoli and 20 g raw daikon radish for 15 days, 100 g broccoli and 10 g daikon radish on day 16)
Study: 16364933
Drug: Selective decontamination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selective decontamination of the digestive tract (SDD) oral gel
Study: 8813907
Drug: Indapamide (IND)
Normalized name: Indapamide
DrugBank: Indapamide (DB00808)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Indapamide (IND) 2.5 mg daily
Study: 8813907
Drug: Hydrochlorothiazide (HCT)
Normalized name: Hydrochlorothiazide
DrugBank: Hydrochlorothiazide (DB00999)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hydrochlorothiazide (HCT) 50 mg daily
Study: 8813907
Drug: Hydrochlorothiazide (HCT)
Normalized name: Hydrochlorothiazide
DrugBank: Hydrochlorothiazide (DB00999)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hydrochlorothiazide (HCT) 12.5 mg and 25 mg daily
Study: 14621725
Drug: ganciclovir, 5
Normalized name: Ganciclovir, 500 mg oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: ganciclovir, 5 mg/kg twice daily (n = 12)
Study: 14621725
Drug: no treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: no treatment (n = 11)
Study: 4019541
Drug: Cefazolin (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefazolin (25 mg/kg IV)
Study: 4019541
Drug: Cefamandole (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefamandole (25 mg/kg IV)
Study: 4019541
Drug: Cefoxitin (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefoxitin (25 mg/kg IV)
Study: 29933528
Drug: Chemotherapy combined
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy combined with CZBG (4 g, twice daily)
Study: 12386036
Drug: Oral pristinamycin
Normalized name: pristinamycin
DrugBank: Pristinamycin (DB13704)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral pristinamycin
Study: 12386036
Drug: Intravenous then
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous then oral penicillin
Study: 7589027
Drug: Propranolol (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol (40 mg) in sauna sessions
Study: 7589027
Drug: Captopril (12.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril (12.5 mg) in sauna sessions
Study: 7589027
Drug: Captopril (12.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril (12.5 mg) in control sessions
Study: 7589027
Drug: Propranolol (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol (40 mg) in control sessions
Study: 2124433
Drug: surgery +
Approvals — FDA: no, EMA: no, PMDA: no
Description: surgery + MMC + 5‐FU (chemotherapy)
Study: 7314008
Drug: 1 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg/kg aminophylline
Study: 7314008
Drug: 6 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 mg/kg aminophylline
Study: 30846366
Drug: Exogenously administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exogenously administered oxytocin (single dose)
Study: 17893574
Drug: Oral gabapentin
Normalized name: Gabapentin
DrugBank: Gabapentin (DB00996)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral gabapentin 800 mg
Study: 11474662
Drug: Alefacept 0.025
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alefacept 0.025 mg/kg
Study: 11474662
Drug: Alefacept 0.075
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alefacept 0.075 mg/kg
Study: 11474662
Drug: Alefacept 0.150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alefacept 0.150 mg/kg
Study: 2837830
Drug: Adjuvant CAP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant CAP chemotherapy
Study: 2837830
Drug: Chemotherapy alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy alone or in combination with radiation therapy
Study: 2837830
Drug: Preoperative therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preoperative therapy (chemotherapy alone or combination with radiation) followed by adjuvant chemotherapy
Study: 2837830
Drug: Therapy directed
Normalized name: Chimeric Antigen Receptor immunotherapy directed against CLL-1 and CD33
DrugBank: CLL1-CD33 compound chimeric antigen receptor T cells (DB18568)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Therapy directed at CNS disease
Study: 21707327
Drug: Testosterone gel
Normalized name: Androgel 1.62% Metered Dose Pump Testosterone Gel
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Testosterone gel vs Placebo gel
Study: 16443774
Drug: Low-dose insulin
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose insulin (0.3 mU . kg(‐1) . min(‐1)) in HNF-1beta mutation carriers
Study: 16443774
Drug: Low-dose insulin
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose insulin (0.3 mU . kg(‐1) . min(‐1)) in HNF-1alpha mutation carriers
Study: 16443774
Drug: Low-dose insulin
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose insulin (0.3 mU . kg(‐1) . min(‐1)) in control subjects
Study: 16443774
Drug: High-dose insulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose insulin (1.5 mU . kg(‐1) . min(‐1)) in all groups
Study: 11467238
Drug: Combined regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined regimen of acetazolamide and dexamethasone (twice daily for 5 days)
Study: 26147369
Drug: Virosomal vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Virosomal vaccine H5N1 (NIBRG‐14) with Matrix M adjuvant (1.5, 7.5 or 30 μg HA)
Study: 26147369
Drug: Virosomal vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Virosomal vaccine H5N1 (NIBRG‐14) without Matrix M adjuvant (30 μg HA)
Study: 26147369
Drug: Vaccine (with
Normalized name: Pneumococcal Polyvalent-23 Vaccine (with isolate 12)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaccine (with or without Matrix M)
Study: 18469018
Drug: 4 mg
Normalized name: lutein 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg rosiglitazone once daily (n=20)
Study: 12565082
Drug: nisoldipine-ER (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: nisoldipine-ER (20 to 40 mg)
Study: 12565082
Drug: amlodipine (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: amlodipine (5 to 10 mg)
Study: 7698380
Drug: Oxytocin dose
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oxytocin dose increments at 20-min intervals
Study: 7698380
Drug: Oxytocin dose
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oxytocin dose increments at 60-min intervals
Study: 7795283
Drug: Ranitidine (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine (150 mg nocte)
Study: 2693231
Drug: Sucralfate (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sucralfate (1 g tds)
Study: 356245
Drug: Diclofenac sodium
Normalized name: Diclofenac Sodium
DrugBank: Diclofenac (DB00586)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Diclofenac sodium (Voltaren) 125 mg daily
Study: 27994091
Drug: Etanercept (E)
Normalized name: Etanercept
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Etanercept (E) therapy
Study: 27994091
Drug: Triple therapy
Normalized name: MigreLief Triple Therapy with Puracol Caplet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple therapy (T)
Study: 25804278
Drug: Thrombogenicity indices
Normalized name: Hemidesmus indicus root extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thrombogenicity indices and cell adhesion molecules
Study: 23482999
Drug: 1% mepivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% mepivacaine (0.9 ml injected)
Study: 9014960
Drug: Training twice
Normalized name: Tice BCG
DrugBank: Bacillus calmette-guerin substrain tice live antigen (DB10343)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Training twice a week (2x/wk, n = 17)
Study: 8204875
Drug: Cranial radiotherapy
Normalized name: geranial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cranial radiotherapy (cRT) plus prolonged triple intrathecal (IT) therapy with methotrexate (MTX), cytarabine, and prednisone.
Study: 8204875
Drug: No cranial
Approvals — FDA: no, EMA: no, PMDA: no
Description: No cranial radiotherapy (cRT) but prolonged triple IT therapy.
Study: 8204875
Drug: Neither cRT
Normalized name: 2,2',3,3',4,4',5,5',6-nonachlorodiphenyl either
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neither cRT nor prolonged triple IT therapy.
Study: 23948001
Drug: Motivational tobacco
Normalized name: Tobacco leaf
DrugBank: Tobacco leaf (DB10710)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Motivational tobacco cessation treatment combined with nicotine replacement
Study: 22329473
Drug: Memantine (starting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Memantine (starting dose of 5 mg increased up to 20 mg over four weeks, then stable dose of 20 mg from four to eight weeks)
Study: 22329473
Drug: Placebo (matching
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (matching pill)
Study: 20151970
Drug: bupropion SR
Normalized name: Bupropion Hydrochloride 100 MG Oral Tablet, Extended Release, 12 HR [BUPROPION SR]
DrugBank: Bupropion (DB01156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: bupropion SR 150 mg/daily
Study: 19375168
Drug: Intravitreal perfluoropropane
Normalized name: pentafluoropropane
DrugBank: Pentafluoropropane (DB13117)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravitreal perfluoropropane (C3F8) gas injection (group A)
Study: 16974189
Drug: bupropion XL
Normalized name: Bupropion Hydrochloride 150 MG Oral Tablet, Extended Release [BUPROPION XL]
DrugBank: Bupropion (DB01156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: bupropion XL (300-450 mg/d)
Study: 16974189
Drug: venlafaxine XR
Normalized name: venlafaxine Extended Release Oral Capsule
DrugBank: Venlafaxine (DB00285)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: venlafaxine XR (150-225 mg/d)
Study: 12764337
Drug: Cyclobenzaprine with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclobenzaprine with ibuprofen
Study: 11195030
Drug: 0 microg
Normalized name: Digoxin 250 microgram oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0 microg LPS (saline treatment)
Study: 8349477
Drug: Flunarizine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flunarizine (10 mg)
Study: 30098076
Drug: Melatonin 6
Normalized name: melatonin 6 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Melatonin 6 mg/d orally from 3 days before surgery to 3 days after surgery
Study: 30098076
Drug: Vehicle treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vehicle treatment in rats
Study: 30098076
Drug: Oral placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral placebo treatment in patients
Study: 26223941
Drug: Teduglutide (TED)
Normalized name: Teduglutide
DrugBank: Teduglutide (DB08900)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Teduglutide (TED) 0.05 mg/kg daily subcutaneous
Study: 24258773
Drug: IV famotidine
Normalized name: Famotidine
DrugBank: Famotidine (DB00927)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IV famotidine 12 mg/m²
Study: 24258773
Drug: IV ranitidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV ranitidine 60 mg/m²
Study: 22321909
Drug: Propranolol (noradrenergic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol (noradrenergic antagonist)
Study: 20147856
Drug: Oral S-1
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral S-1 (60 mg/m/d, twice a day) from days 1 to 14 with gemcitabine (1000 mg/m/d) on days 1 and 8 (arm A)
Study: 20147856
Drug: Oral S-1
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral S-1 (60 mg/m/d, twice a day) from days 1 to 14 with gemcitabine (1000 mg/m/d) on days 8 and 15 (arm B)
Study: 2029414
Drug: External-beam radiation
Normalized name: allantoin
DrugBank: Allantoin (DB11100)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: External-beam radiation therapy
Study: 31931924
Drug: Intraperitoneal bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraperitoneal bupivacaine (20 ml 0.5% bupivacaine in 480 ml normal saline)
Study: 25899791
Drug: Propranolol (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol (40 mg, single oral dose)
Study: 24042024
Drug: Any oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Any oral NSAIDs
Study: 24042024
Drug: Highest users
Approvals — FDA: no, EMA: no, PMDA: no
Description: Highest users of non-aspirin NSAIDs
Study: 24042024
Drug: Highest users
Approvals — FDA: no, EMA: no, PMDA: no
Description: Highest users of low-dose aspirin
Study: 19873914
Drug: Scalp point
Approvals — FDA: no, EMA: no, PMDA: no
Description: Scalp point injection of 0.5‐1 mL brain protein hydrolysate into acupoints (Baihui (GV 20), Fengchi (GB 20), motor area)
Study: 19873914
Drug: Intravenous drip
Normalized name: DRIP COLLECTOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous drip of 10 mL brain protein hydrolysate
Study: 18294442
Drug: Ciprofloxacin (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciprofloxacin (500 mg every 12 h for 10 days)
Study: 18294442
Drug: Nitrofurantoin (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitrofurantoin (100 mg every 6 h for 10 days)
Study: 18294442
Drug: Trimethoprim-sulfamethoxazole (TMP-SMX)
Normalized name: sulfamethoxazole / trimethoprim
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trimethoprim-sulfamethoxazole (TMP-SMX) (160/800 mg every 12 h for 10 days)
Study: 15591651
Drug: Pentoxifylline (PTX)
Normalized name: Pentoxifylline
DrugBank: Pentoxifylline (DB00806)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pentoxifylline (PTX) at 10 mg/kg
Study: 11204663
Drug: Oxaliplatin as
Normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oxaliplatin as monotherapy
Study: 21872935
Drug: Intravitreal ranibizumab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravitreal ranibizumab (0.3 mg)
Study: 21872935
Drug: Control treatment
Normalized name: SALICYLIC ACID 190 mg in 1 mL TOPICAL LIQUID [Derma E Acne Blemish Control Treatment Serum]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control treatment (verteporfin photodynamic therapy [PDT] and sham intravitreal injections)
Study: 17274862
Drug: Cocaine 4%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cocaine 4% solution
Study: 12546311
Drug: Low-dose oral
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose oral granisetron plus intravenous dexamethasone (gran/dex)
Study: 12546311
Drug: High-dose metoclopramide
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose metoclopramide plus intravenous dexamethasone (met/dex)
Study: 10051936
Drug: Endotracheal lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Endotracheal lidocaine (0.4 ml lidocaine 8% spray)